Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Lithea AB currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, showing a diversification of the current workload. For a portfolio of this size, having 2 distinct examiners means that each pending matter is being evaluated independently, without the influence of a shared examiner's perspective.
The busiest examiner, BROWE, DAVID, is currently handling 1 busiest examiner pending action. Since there are 2 distinct examiners in total, the workload is split, with each examiner managing 1 of the 2 pending office actions. This distribution across 2 distinct art units suggests that the company's Biotechnology & Pharmaceuticals innovations are being categorized into different technical sub-specialties.
Practitioners must manage 2 pending office actions that may follow different timelines and examination styles due to the involvement of 2 distinct art units. The presence of 1 busiest examiner pending action indicates that no single examiner dominates the firm's current patent office interactions. This variety requires a tailored approach for each of the 2 pending office actions to address the specific concerns of the 2 distinct examiners involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BROWE, DAVID | 1 | 26.4% | +27.3% |
| ROGERS, JAMES WILLIAM | 1 | 46.2% | +22.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247740 | NOVEL TREATMENT REGIMEN OF CANCER | BROWE, DAVID | 26d overdue |
| 17665316 | TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES | ROGERS, JAMES WILLIAM | 2d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247740 | NOVEL TREATMENT REGIMEN OF CANCER | BROWE, DAVID | 26d overdue |
| 17665316 | TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES | ROGERS, JAMES WILLIAM | 2d overdue |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18247740 | NOVEL TREATMENT REGIMEN OF CANCER | BROWE, DAVID | 1617 | §103 | Final Rejection | 26d overdue | Pending | Apr 03, 2023 |
| 17665316 | TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES | ROGERS, JAMES WILLIAM | 1618 | §103§112 | Final Rejection | 2d overdue | Pending | Feb 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial